GIPR Antagonist

About Ambrosia Biosciences

Ambrosia Biosciences is a preclinical-stage drug discovery company targeting metabolic diseases, particularly obesity, with orally bioavailable small molecules. The company's core strategy is to apply an integrated platform combining cryo-EM structural biology, biophysics, and AI-powered design to tackle Class B GPCRs, a validated but underexploited target class. With a seasoned leadership team and a pipeline centered on GLP-1R, GIPR, and amylin receptor modulators, Ambrosia aims to develop best-in-class oral therapies that could offer significant advantages over current injectable peptide drugs. The company is currently pre-revenue and privately held.

Therapeutic Areas

Other Obesity/Metabolic Disorders Drugs